Company Filing History:
Years Active: 1985-2002
Title: S Jane De Solms: Innovator in Oncogene Research
Introduction
S Jane De Solms is a notable inventor based in Norristown, PA (US). He has made significant contributions to the field of oncology through his innovative research and development of therapeutic compounds. With a total of 4 patents, his work focuses on inhibiting key processes involved in cancer progression.
Latest Patents
His latest patents include groundbreaking inventions such as "Inhibitors of Prenyl-Protein Transferase" and "Inhibitors of Farnesyl-Protein Transferase." The first invention is directed towards peptidomimetic macrocyclic compounds that inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. This invention also encompasses chemotherapeutic compositions containing these compounds and methods for their application. The second patent focuses on compounds that inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras, along with related chemotherapeutic compositions and methods.
Career Highlights
S Jane De Solms is currently associated with Merck & Company, Inc., where he continues to advance his research in the pharmaceutical field. His work has been instrumental in developing new therapeutic strategies for cancer treatment.
Collaborations
He has collaborated with esteemed colleagues such as Samuel L Graham and John S Wai, contributing to a rich environment of innovation and discovery.
Conclusion
S Jane De Solms stands out as a prominent figure in oncogene research, with a focus on developing innovative therapeutic solutions. His contributions are paving the way for advancements in cancer treatment and improving patient outcomes.